Who
Kristine Peterson
Director
Company insider
Files Form 4 as: Director, Mineralys Therapeutics; Director, ArriVent BioPharma; Director, Immunocore Holdings; Director, Enanta Pharmaceuticals; Director, ImmunoGen; Director, Paratek Pharmaceuticals; Director, Amarin Corporation; Director, EyePoint.
In numbers
- Trades disclosed
- 123
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $3.9M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 10 Jul 2012
- Last trade
- 19 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 20 Oct 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,400 at $0.00 | filing |
| 19 Oct 2026filed 20 Oct 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,492 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,492 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,502 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,198 at $0.00 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,534 at $0.00 | filing |
| 22 Apr 2024filed 23 Apr 2024 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,587 at $0.00 | filing |
| 6 Mar 2024filed 8 Mar 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —13,090 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —74,954 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
| 12 Feb 2024filed 12 Feb 2024 | ImmunoGenoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
News
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coatsmanilatimes.net · 19 Oct 2026Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKKGY) Financial ReviewAMRN · themarketsdaily.com · 11 Oct 2026
1 headline in the last 90 days name Kristine Peterson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.